Why did you say that you sold the Biosector business to Croda?

The reason is that Brenntag is a distributor. We are not a manufacturing company. We don't want to compete with our principals or our customers. The majority of vaccine producers buy different products from franchises like GSK. They are our customers, and we cannot go into the market and compete with them. First, from a rational point of view. Second, regarding the manufacturing process, we are not manufacturers and do not want to be. We are distributors. We buy the finished product, stock it, and sell it.

Why is Croda so well-positioned in biotech?

The second point is in the UK market. I think the Minister of Health in the UK is providing some financial support for adjuvant development, specifically the next generation of adjuvant development. I can find the data on that. I don't have it with me now, but I can find the real data to support your research. Croda is not the number one player in the adjuvant market in terms of volume and value. However, they are positioned in the specialty adjuvant market, and they are developing significant knowledge in biotech.